Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Introduction: Classical Hodgkin lymphoma (cHL) is among the most common malignancies in adolescents and young adults. High-dose chemotherapy (HDCT) and autologous hematopoietic stem cell transplantation (ASCT) are standard for most patients with relapsed/refractory (R/R) disease. Current salvage therapies are associated with excessive toxicity and variable complete remission rates (Harker-Murray et al, Pediatr Blood Cancer 2014). Novel regimens that increase remission rates and reduce late effects of therapy are needed, particularly for young patients. Nivolumab (nivo) is a fully human IgG4 anti-programmed death-1 monoclonal antibody. Brentuximab vedotin (BV) is a CD30-directed antibody-drug conjugate. In a phase 1/2 study of adults with R/R cHL, the combination of nivo + BV was well tolerated, with a high response rate as first salvage regimen (Herrera et al, Blood 2018). CheckMate 744 (AHOD1721; NCT02927769) is the first risk-stratified, response-adapted, phase 2 study of nivo + BV, followed by BV + bendamustine for suboptimal response, in children, adolescents, and young adults with R/R cHL with low or standard risk of relapse. Here we report preliminary, investigator (INV)-assessed results from the standard-risk (R2) cohort.Methods: This open-label study enrolled patients aged 5-30 years with pathologically confirmed cHL, excluding nodular lymphocyte-predominant HL, after failure/non-response to first-line therapy and without prior ASCT. Stratification to R2 was based on ...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches Source Type: research

Related Links:

The objective of this review was to determine whether in previously untreated adults with HL (all stages) receiving first-line therapy, interim PET scan results (i.e. a positive or a negative result) can distinguish between those with a poor prognosis and those with a better prognosis, and thereby predict survival in each group.How many studies were included? What was included and what was excluded?We included twenty-three studies in total, in this review. In all studies, interim PET was conducted during first-line therapy and after two, three, and/or four cycles of chemotherapy in adults with HL (all stages). We included ...
Source: Cochrane News and Events - Category: Information Technology Authors: Source Type: news
This study was supported in part by the National Cancer Center Research and Development Fund (25-A-7 and 28-A-8); Health and Labor Science Research Grants for Clinical Research, Japan; and joint research funding from Takeda Pharmaceutical Co, Ltd.; Noile-Immune Biotech Inc.; Ono Pharmaceutical Co., Ltd.; BrightPath Biotherapeutics Co., Ltd.; and Sysmex Co., Ltd. This study was performed as part of a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan. Conflict of Interest Statement TN, TS, and TY ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Hodgkin Lymphoma (HL) accounts for approximately 10% of lymphomas and .5% of cancer cases in the United States. An estimated 8260 new cases and 1070 deaths annually occur due to HL, with most patients affected being young adults [1]. Due to advances in treatment, the prognosis for patients diagnosed with HL is excellent, and most patients are cured with first-line therapy. However, despite the relatively high long-term overall survival (OS) for HL patients, approximately 20% to 30% of patients have refractory or relapsed disease [2].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Hodgkin's Lymphoma (HL) accounts for approximately 10% of lymphomas and 0.5% of cancer cases in the United States. There is an estimated 8260 new cases and 1070 deaths annually due to HL with a majority of patients affected being young adults [1]. Due to advances in treatment, the prognosis for patients diagnosed with HL is excellent and most patients are cured with first-line therapy. However, despite the relatively high long-term overall survival for HL patients, approximately 20-30% patients have refractory or relapsed disease [2].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Hodgkin Lymphoma (HL) is a B-cell lymphoid malignancy usually affecting young adults 20 –34 years old (yr) [1]. Prognosis of HL patients is usually excellent, with a 5-year relative survival rate reaching 86.6% for patients diagnosed in the period 2008–2014 [2]. Radiation therapy (RT) has a key role in the management of HL patients [3,4]. However, the use of RT has been associate d with late effects, including the development of secondary malignancies [5–7]. HL patients present statically significant increased risk of developing second cancer for at least 40 yrs after irradiation [8].
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Original paper Source Type: research
Introduction: Hodgkin lymphoma (HL) is a rare disease that commonly occurs in AYAs, defined in the United States as patients 15 to 39 years of age. Brentuximab vedotin (Adcetris®; A) is an anti-CD30 antibody-drug conjugate approved for adult patients with previously untreated stage III or IV classical HL (cHL) in combination with doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy based on results from the phase 3 ECHELON-1 trial which demonstrated a significantly improved modified progression-free survival (mPFS) compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) (HR, 0.77; 95% CI, 0.60-...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster I Source Type: research
Conclusions: We report a high rate of guideline-driven care for AYAs with acute leukemia and lymphoma seen by a multidisciplinary team solely focused on AYA care delivery within a community practice setting. Metrics are derived from best practices from both pediatric (pediatric inspired therapy in AML, ALL; sedation for procedures) and adult (ABVD for HL, NCI and pharma-sponsored trials) oncology paradigms. Immersive AYA programs in non-academic settings are potentially effective models of reducing health disparities and improving outcomes in AYAs.Table 1.DisclosuresCrosswell: Seattle Genetics: Other: stock ownership in Seattle Genetics.
Source: Blood - Category: Hematology Authors: Tags: 902. Health Services Research-Malignant Diseases: Poster III Source Type: research
CONCLUSIONS: This is one of the best characterized prospective cohorts of non-pediatric BL in SSA, which occurred primarily among adolescents and young adults. Outcomes were worse than pediatric cohorts from the region, with most deaths due to progressive BL. This study highlights the need to develop effective treatments for non-pediatric BL with and without HIV in resource-limited settings, where high-intensity strategies from high-income countries may have limited applicability.DisclosuresFedoriw: ALEXION PHARMACEUTICALS: Consultancy, Honoraria.
Source: Blood - Category: Hematology Authors: Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Poster III Source Type: research
Conclusion: In AYAs diagnosed with HL between 2000 and 2015, NHB patients had worse survival compared with NHW and API patients. The higher probability of survival in NHW patients was accompanied by a consistently higher proportion of non-cancer related death in this cohort both 10- years and 15-years after diagnosis. Studies are needed to evaluate risk factors for both short- and long-term mortality in AYAs, and to examine how these risks differ across racial/ethnic groups. Findings also suggest that despite increasing use of response-adapted therapy over the past two decades, all AYAs with HL remain at risk of death in t...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions: Poster III Source Type: research
ConclusionThis is the first pharmacogenomics study of BIP in South East Asian patients, looking at both candidate gene and GWAS analyses. Our results suggest that iron regulation could be the driver in the etiopathogenesis of BIP, supporting the utility of H63D testing in the risk stratification of patients receiving Bleomycin. Moreover, GWAS analyses have discovered 4 novel markers that suggest an association with BIP, which will be further evaluated and should be independently replicated in a larger cohort.DisclosuresChng: Celgene: Consultancy, Honoraria, Other: Travel, accommodation, expenses, Research Funding; Takeda: ...
Source: Blood - Category: Hematology Authors: Tags: 621. Lymphoma-Genetic/Epigenetic Biology: Poster III Source Type: research
More News: Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Chemotherapy | Children | Databases & Libraries | Employment | Genetics | Hodgkin's Disease | Lymphoma | Radiation Therapy | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants | Treanda